Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy is ongoing.
November 7, 2019: Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress
October 24, 2019: Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th
October 18, 2019: Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team